Phathom Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PHAT Nasdaq 2834 www.phathompharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Phathom Pharmaceuticals, Inc.

PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Jul 30th, 2026 4:09 pm
Phathom Pharmaceuticals Q2 Earnings Call Highlights - Jul 30th, 2026 1:04 pm
Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ... - Jul 30th, 2026 1:01 pm
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2 - Jul 30th, 2026 8:30 am
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - Jul 30th, 2026 4:59 am
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 - Jul 20th, 2026 6:00 am
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) - Jun 23rd, 2026 5:59 am
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - May 22nd, 2026 6:00 am
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting - May 20th, 2026 6:00 am
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline - May 5th, 2026 4:12 am
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks - May 3rd, 2026 4:08 am
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - May 1st, 2026 6:00 am
Phathom Pharmaceuticals Q1 Earnings Call Highlights - Apr 30th, 2026 7:41 pm
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Apr 30th, 2026 6:48 pm
Phathom (PHAT) Q1 2026 Earnings Transcript - Apr 30th, 2026 3:16 pm
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Apr 30th, 2026 6:30 am
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - Apr 30th, 2026 4:59 am
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 - Apr 20th, 2026 6:00 am
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder Return - Apr 16th, 2026 10:29 pm
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - Apr 13th, 2026 11:00 am